EuKedos S.p.A.

BIT:EUK Stock Report

Market Cap: €18.4m

EuKedos Past Earnings Performance

Past criteria checks 5/6

EuKedos has been growing earnings at an average annual rate of 32.9%, while the Healthcare industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 1.2% per year. EuKedos's return on equity is 2.4%, and it has net margins of 1.4%.

Key information

32.9%

Earnings growth rate

32.9%

EPS growth rate

Healthcare Industry Growth16.7%
Revenue growth rate-1.2%
Return on equity2.4%
Net Margin1.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

The Returns At EuKedos (BIT:EUK) Aren't Growing

Mar 15
The Returns At EuKedos (BIT:EUK) Aren't Growing

EuKedos (BIT:EUK) Seems To Be Using A Lot Of Debt

Oct 14
EuKedos (BIT:EUK) Seems To Be Using A Lot Of Debt

EuKedos (BIT:EUK) Is Doing The Right Things To Multiply Its Share Price

Aug 10
EuKedos (BIT:EUK) Is Doing The Right Things To Multiply Its Share Price

Is EuKedos (BIT:EUK) Using Too Much Debt?

May 03
Is EuKedos (BIT:EUK) Using Too Much Debt?

Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of Return

Mar 07
Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of Return

EuKedos (BIT:EUK) Seems To Be Using A Lot Of Debt

Oct 30
EuKedos (BIT:EUK) Seems To Be Using A Lot Of Debt

Some Investors May Be Worried About EuKedos' (BIT:EUK) Returns On Capital

Sep 04
Some Investors May Be Worried About EuKedos' (BIT:EUK) Returns On Capital

Here's Why EuKedos (BIT:EUK) Is Weighed Down By Its Debt Load

May 06
Here's Why EuKedos (BIT:EUK) Is Weighed Down By Its Debt Load

Would EuKedos S.p.A. (BIT:EUK) Be Valuable To Income Investors?

Mar 22
Would EuKedos S.p.A. (BIT:EUK) Be Valuable To Income Investors?

Our Take On EuKedos' (BIT:EUK) CEO Salary

Dec 07
Our Take On EuKedos' (BIT:EUK) CEO Salary

Revenue & Expenses Breakdown

How EuKedos makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BIT:EUK Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2451100
31 Mar 2450100
31 Dec 2349100
30 Sep 2349000
30 Jun 2348000
31 Mar 2348000
31 Dec 2247000
30 Sep 2247100
30 Jun 2247100
31 Mar 2246100
31 Dec 2145100
30 Sep 2144000
30 Jun 2144-100
31 Mar 2145-100
31 Dec 2047-200
30 Sep 2049-100
30 Jun 2051-100
31 Mar 2052000
31 Dec 1953100
30 Sep 1953120
30 Jun 1952140
31 Mar 1952150
31 Dec 1852170
30 Sep 1851070
30 Jun 1851-270
31 Mar 1851-270
31 Dec 1751-270
30 Sep 1750-170
30 Jun 1750070
31 Mar 1750060
31 Dec 1649060
30 Sep 1652-170
30 Jun 1655-170
31 Mar 1657-170
31 Dec 1559-170
30 Sep 1557-170
30 Jun 1554-170
31 Mar 1556070
31 Dec 1458070
30 Sep 1461060
30 Jun 1464060
31 Mar 1467060

Quality Earnings: EUK has high quality earnings.

Growing Profit Margin: EUK's current net profit margins (1.4%) are higher than last year (0.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: EUK has become profitable over the past 5 years, growing earnings by 32.9% per year.

Accelerating Growth: EUK's earnings growth over the past year (76.2%) exceeds its 5-year average (32.9% per year).

Earnings vs Industry: EUK earnings growth over the past year (76.2%) exceeded the Healthcare industry 15.5%.

Return on Equity

High ROE: EUK's Return on Equity (2.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:07
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EuKedos S.p.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Micaela FerrutaIntermonte SIM S.p.A.
Kevin TempestiniKT & Partners Srl